Table 1.
Vaccine efficacy in 1998 against chronic carriage of hepatitis B virus and breakthrough infection overall by village and by age group
Chronic carriage
Breakthrough infection
No infected in vaccine
v
control
Vaccine efficacy (%) (95% CI)
No infected in vaccine
v
control
Vaccine efficacy (%) (95% CI)
Overall
10/855
v
191/931
94 (89 to 97)
102/847
v
564/929
80 (76 to 84)
Keneba
6/628
v
83/622
93 (84 to 97)
68/624
v
302/620
78 (72 to 82)
Manduar
4/227
v
108/309
95 (87 to 98)
34/223
v
246/309
81 (74 to 86)
<5 years (group 6)
3/235
v
68/354
93 (79 to 98)
14/232
v
140/354
85 (74 to 91)
5-9 years (group 5)
0/225
v
66/309
100
10/224
v
309/509
93 (85 to 96)
10-14 years (group 4)
2/220
v
39/191
96 (82 to 99)
33/220
v
156/190
82 (75 to 87)
15 years (groups 1, 2, 3)
5/175
v
18/77
88 (68 to 95)
53/171
v
68/76
65 (56 to 73)
15
years (groups 1, 2, 3)